Annotation Detail
Information
- Associated Genes
- ERBB2
- Associated Variants
-
ERBB2 OVEREXPRESSION
ERBB2 OVEREXPRESSION - Associated Disease
- pancreatic cancer
- Source Database
- CIViC Evidence
- Description
- This is Phase II trial of Trastuzumab and capecitabine as first line treatment in patients with IHC 3+ HER2 expressing advanced pancreatic cancer or cancer with HER2 gene amplification of stage IVB. Total 207 patients could be assessed for HER2 expression. From the 23 patient with IHC 3+ HER2 expression or IHC 2+ and HER2 gene amplification, 17 patients were included in the study and could be assessed for response to the treatment. Contrary to breast and gastric cancer, only 7 out of 11 (64%) patients with IHC 3+ HER2 expression showed gene amplification. PFS rate at 12 weeks was estimated as 23.5%. Median PFS was 65 days. Median OS was 6.9 months. Authors concluded not to recommend further evaluation of anti-HER2 treatment in patients with metastatic pancreatic cancer.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/5955
- Gene URL
- https://civic.genome.wustl.edu/links/genes/20
- Variant URL
- https://civic.genome.wustl.edu/links/variants/875
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Pancreatic Cancer
- Evidence Direction
- Does Not Support
- Drug
- Capecitabine,Trastuzumab
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 22374460
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Capecitabine | Sensitivity | false |
| Trastuzumab | Sensitivity | false |